Bibliografía del artículo
1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder [Revision]. Am J Psychiatry 159(Suppl.4):1-50, 2002.
2. O'Dowd A. NICE issues new guidance to improve the treatment of bipolar disorder. BMJ 333(7561):220, 2006.
3. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorder (ISBD) collaborative update of CANMAT guidelines fort he management of patients with bipolar disorder: update 2009. Bipolar Disord 11(3):225-55, 2009.
4. Marangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord 8(5 Pt 2):566-75, 2006.
5. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: medication treatment of bipolar disorder 2000. Postgrad Med Spec No:1-104, 2000.
6. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 57(5):660-5, 2006.
7. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 59(10):1175-83, 2008.
8. Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E. The use of antidepressants in bipolar disorder. J Clin Psychiatry 69(8):1307-18, 2008.
9. Bauer M, Zaninelli R, Müller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double blind study. J Clin Psychopharmacol 19(2):164-71, 1999.
10. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157(1):124-6, 2000.
11. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158(6):906-12, 2001.
12. Vieta E, Martínez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 63(6):508-12, 2002.
13. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356(17):1711-22, 2007.
14. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71(2):163-74, 2010.
15. Van der Loos ML, Mulder P, Hartong EG, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand 122(3):246-54, 2010.
16. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4(4):313-22, 1989.
17. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60(11):1079-88, 2003. Erratum in: Arch Gen Psychiatry 61(2):176, 2004.
18. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord 87(1):121-30, 2005.
19. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 67(7):1025-33, 2006.
20. Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 29(4):358-61, 2009.
21. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 12(6):773-82, 2009.
22. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 63(6):508-12, 2002.
23. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189:124-31, 2006. Erratum in: Br J Psychiatry 189:569, 2006.
24. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 28(2):171-81, 2008.
25. Amsterdam JD, Wang CH, Shwarz M, Shults J. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect Disord 112(1-3):219-30, 2009.
26. Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand 121(3):201-8, 2010.
27. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 48(7):910-6, 1991.
28. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 115(5):360-5, 2007.
29. Mallinger AG, Frank E, Thase ME, et al. Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior? Psychopharmacol Bull 42(2):64-74, 2009.
30. Agosti V, Stewart JW. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int Clin Psychopharmacol 22(5):309-11, 2007.
31. Carlson GA, Finch SJ, Fochtmann LJ, et al. Antidepressant-associated switches from depression to mania in severe bipolar disorder. Bipolar Disord 9(8):851-9, 2007.
32. Gao K, Kemp DE, Ganocy SJ, et al. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord 10(8):907-15, 2008.
33. Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 164(9):1348-55, 2007.
34. Frye MA, Helleman G, McElroy SL, Altshuler LL, Black DO, Keck PE Jr, Nolen WA, Kupka R, Leverich GS, Grunze H, Mintz J, Post RM, Suppes T. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 166(2):164-72, 2009.
35. Koszewska I, Rybakowski JK. Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 59(1):12-6, 2009.
36. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71(4):372-80, 2010.
37. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 30(3):306-11, 2010.